Allergan PLC. (AGN) Price Target Cut to $221.00 by Analysts at Royal Bank Of Canada

Allergan PLC. (NYSE:AGN) had its price objective trimmed by Royal Bank Of Canada from $250.00 to $221.00 in a report issued on Thursday. The firm currently has an outperform rating on the stock.

AGN has been the topic of a number of other research reports. J P Morgan Chase & Co set a $275.00 price objective on shares of Allergan PLC. and gave the stock a buy rating in a research note on Sunday, October 22nd. BidaskClub lowered shares of Allergan PLC. from a sell rating to a strong sell rating in a research note on Friday, August 25th. Mizuho restated a buy rating and set a $267.00 price target on shares of Allergan PLC. in a research report on Monday, September 25th. Wells Fargo & Company restated an outperform rating and set a $258.00 price target on shares of Allergan PLC. in a research report on Wednesday, October 18th. Finally, Citigroup Inc restated a buy rating and set a $280.00 price target on shares of Allergan PLC. in a research report on Wednesday, September 20th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have issued a buy rating to the company. Allergan PLC. currently has an average rating of Hold and a consensus price target of $246.73.

Shares of Allergan PLC. (NYSE AGN) traded down $9.66 during trading on Thursday, reaching $174.92. 3,283,512 shares of the company’s stock were exchanged, compared to its average volume of 4,520,000. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.13 and a quick ratio of 1.10. Allergan PLC. has a twelve month low of $169.64 and a twelve month high of $256.80. The firm has a market cap of $58.33 billion, a price-to-earnings ratio of 11.37, a price-to-earnings-growth ratio of 0.93 and a beta of 1.12.

Allergan PLC. (NYSE:AGN) last issued its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.06 by $0.09. The business had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.04 billion. Allergan PLC. had a negative net margin of 47.27% and a positive return on equity of 7.86%. Allergan PLC.’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.32 EPS. equities research analysts anticipate that Allergan PLC. will post 16.28 EPS for the current fiscal year.

WARNING: “Allergan PLC. (AGN) Price Target Cut to $221.00 by Analysts at Royal Bank Of Canada” was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.com-unik.info/2017/11/04/allergan-plc-agn-price-target-cut-to-221-00-by-analysts-at-royal-bank-of-canada.html.

Allergan PLC. declared that its Board of Directors has initiated a share repurchase program on Monday, September 25th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to reacquire up to 2.8% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s leadership believes its shares are undervalued.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Friday, November 17th will be issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.60%. The ex-dividend date of this dividend is Thursday, November 16th. Allergan PLC.’s dividend payout ratio (DPR) is currently -12.39%.

Institutional investors have recently modified their holdings of the stock. Honeywell International Inc. lifted its stake in Allergan PLC. by 13.6% in the second quarter. Honeywell International Inc. now owns 168,130 shares of the company’s stock worth $40,871,000 after acquiring an additional 20,100 shares during the last quarter. Israel Discount Bank of New York purchased a new position in Allergan PLC. in the first quarter worth approximately $988,000. Sumitomo Life Insurance Co. lifted its position in shares of Allergan PLC. by 39.0% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 15,122 shares of the company’s stock worth $3,099,000 after buying an additional 4,244 shares during the last quarter. Colony Group LLC lifted its position in shares of Allergan PLC. by 9.9% during the 2nd quarter. Colony Group LLC now owns 39,802 shares of the company’s stock worth $9,675,000 after buying an additional 3,577 shares during the last quarter. Finally, Palladium Partners LLC lifted its position in shares of Allergan PLC. by 1.7% during the 2nd quarter. Palladium Partners LLC now owns 31,161 shares of the company’s stock worth $7,575,000 after buying an additional 523 shares during the last quarter. Institutional investors own 82.02% of the company’s stock.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

What are top analysts saying about Allergan PLC.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Allergan PLC. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit